Disease‐modifying Drugs for Multiple Sclerosis in Japan: A Focus on the 2017 Japanese Guidelines and the 2018 Supplement
Clinical and Experimental Neuroimmunology - United Kingdom
doi 10.1111/cen3.12502
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2019
Authors
Publisher
Wiley